An intergroup phase III clinical trial of metformin versus
placebo in early stage breast cancer is currently ongoing. This
trial has recurrence-free and overall survival as study endpoints
and will explore whether the anticancer effect of metformin
is related to an insulin-dependent or -independent
mechanism (ClinicalTrials.gov identifier NCT01101438